Regeneron Pharmaceuticals (REGN) Receives “Hold” Rating from Royal Bank of Canada

Royal Bank of Canada reaffirmed their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report sent to investors on Thursday morning. The firm currently has a $430.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also commented on REGN. BTIG Research reiterated a buy rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 22nd. Piper Jaffray Companies reiterated an overweight rating and issued a $540.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, September 29th. Oppenheimer reiterated a hold rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, September 27th. SunTrust Banks reiterated a hold rating and issued a $435.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, October 2nd. Finally, Citigroup lowered shares of Regeneron Pharmaceuticals from a buy rating to a neutral rating and dropped their price target for the company from $480.00 to $380.00 in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, seventeen have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Regeneron Pharmaceuticals currently has a consensus rating of Hold and an average target price of $465.40.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up $5.83 during trading on Thursday, reaching $388.95. 1,271,116 shares of the company’s stock traded hands, compared to its average volume of 903,586. The stock has a market capitalization of $41,543.44, a price-to-earnings ratio of 33.48, a P/E/G ratio of 1.52 and a beta of 1.53. Regeneron Pharmaceuticals has a one year low of $340.09 and a one year high of $543.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm’s revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the firm posted $3.13 earnings per share. sell-side analysts predict that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current year.

In related news, Director Charles A. Baker sold 2,000 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at $4,950,000. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. 10.80% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. lifted its holdings in Regeneron Pharmaceuticals by 20.6% in the second quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock valued at $3,441,000 after acquiring an additional 1,199 shares during the period. Dupont Capital Management Corp purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $220,000. Shell Asset Management Co. increased its position in shares of Regeneron Pharmaceuticals by 24.1% in the third quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock valued at $5,565,000 after buying an additional 2,999 shares in the last quarter. Blair William & Co. IL increased its position in shares of Regeneron Pharmaceuticals by 4.8% in the second quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock valued at $841,000 after buying an additional 79 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 2.4% in the second quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after buying an additional 2,646 shares in the last quarter. 66.67% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.com-unik.info/2017/12/15/regeneron-pharmaceuticals-regn-receives-hold-rating-from-royal-bank-of-canada.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit